| Hard to Treat Diseases (HTDS) Corporate Management Update |
|
Shenzhen, China (MMD Newswire) Sept 3, 2010 -- Hard to Treat Diseases, Inc. (HTDS; http://www.htdsmedical.com)informs shareholders and followers that the company has retained a Texas-based lawyer who has visited Shenzhen Mellow Hope offices and operations in China. The lawyer is currently in the process of issuing a legal opinion and completing adequate disclosure, which will be filed with OTC Markets in an effort to have the skull and bones rank removed from the HTDS quotes. HTDS has completed the sale of former subsidiary Collegenna Skin Care Products, to Axia (AGIJ). and payment is due shortly. The company is currently negotiating the sale of subsidiary Slavica Biochem, as it intends to focus on its core business, namely vaccine sales and distribution. HTDS is mindful that its share price is suppressed. The company is of the opinion that once the skull and bones ranking is removed, HTDS share value will rise or at least resume to some respectable level. To address this issue, company management continues to cooperate with Pink Sheets and hopes to resolve the CE ranking. In other news and updates, the company is doing brisk business, continuing to expand sales, attract new markets, and sign new agreements. HTDS realizes this news is not enough to satisfy shareholders' desire to see the share price return to prior levels, and management continues looking for opportunities to restore values which may include amalgamations and a merger. About Mina Mar Group: Mina Mar Group, MMG offers full corporate services to public companies from filings, compliance and corporate governance matters. MMG pioneered the industry first "Go Public Free" program, the first OTC Markets firm to challenge the short sellers, stock bashers and repeal of the "Communication Decency Act". Visitwww.minamargroup.com/iceto learn more andwww.stockbasher.comto participate as a shareholder of the issuer. Mina Mar Marketing Group, MMMG (www.minamargroup.net) offers publicly traded companies full array of services such as Investor Relations, maintenance and investor awareness. To be included in company's email database for press releases, "Friday Tips", Monday Analysis industry updates, and various client companies activities and updates that may or may not be news worthy or news released, please subscribe for opt-in mailer athttp://www.minamargroup.com/updates. Safe Harbor Statement Information in this news release may contain statements about future expectations, plans, prospects or performance of Hard to Treat Diseases, Inc. that constitute forward-looking statements for purposes of the Safe Harbor Provisions under the Private Securities Litigation Reform Act of 1995. The words or phrases "can be," "expects," "may affect," "believed," "estimate," "project" and similar words and phrases are intended to identify such forward-looking statements. Hard to Treat Diseases, Inc. cautions you that any forward-looking information provided by or on behalf of Hard to Treat Diseases, Inc. is not a guarantee of future performance. None of the information in this press release constitutes or is intended as an offer to sell securities or investment advice of any kind. Hard to Treat Diseases, Inc.'s actual results may differ materially from those anticipated in such forward-looking statements as a result of various important factors, some of which are beyond Hard to Treat Diseases, Inc.'s control. In addition to those discussed in Hard to Treat Diseases, Inc.'s press releases, public filings, and statements by Hard to Treat Diseases, Inc.'s management, including, but not limited to, Hard to Treat Diseases, Inc.'s estimate of the sufficiency of its existing capital resources, Hard to Treat Diseases, Inc.'s ability to raise additional capital to fund future operations, Hard to Treat Diseases, Inc.'s ability to repay its existing indebtedness, the uncertainties involved in estimating market opportunities, and in identifying contracts which match Hard to Treat Diseases, Inc.'s capability to be awarded contracts. All such forward-looking statements are current only as of the date on which such statements were made. Hard to Treat Diseases, Inc. does not undertake any obligation to publicly update any forward-looking statement to reflect events or circumstances after the date on which any such statement is made or to reflect the occurrence of unanticipated events. Investor Relations: Tel: 1-647-426-1640;www.minamargroup.net/helpdesk, Investor Relations Department Inquiry,www.minamargroup.net(IR), for (M&A) and Corporate Matters,www.minamargroup.com read full article |
Search:
Custom Search